Back to Search
Start Over
Prognostic significance of a novel indicator (PSApostd3/PSApre) for PSA recurrence in patients after radical prostatectomy
- Source :
- Cancer Management and Research. 11:5777-5783
- Publication Year :
- 2019
- Publisher :
- Informa UK Limited, 2019.
-
Abstract
- Purpose Radical prostatectomy (RP) is a common treatment for prostate cancer, but a fraction of patients may experience PSA recurrence after surgery, manifesting as an elevation in prostate specific antigen (PSA). Vast literature has reported different prognostic factors for PSA recurrence without reaching a consensus. This retrospective study investigated the efficacy of a new indicator in predicting PSA recurrence in patients after RP. Patients and methods From October 2000 to December 2015, 102 PCa patients who underwent laparoscopic prostatectomy in the Urology Department of Peking Union Medical College Hospital were analyzed. We calculated PSApostd3/PSApre, defined as the ratio of the PSA on day 3 postop as the numerator and the pre-operative PSA as the denominator, in these patients to represent PSA decrement after surgery, and investigated its relationship with PSA recurrence during follow-up. Results The receiver operating characteristic (ROC) curve of PSApostd3/PSApre derived a cut-off at 0.453 (sensitivity=0.704, specificity=0.853, P
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Receiver operating characteristic
business.industry
Prostatectomy
medicine.medical_treatment
Urology
Retrospective cohort study
urologic and male genital diseases
Logistic regression
medicine.disease
03 medical and health sciences
Prostate-specific antigen
Exact test
Prostate cancer
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
medicine
T-stage
business
Subjects
Details
- ISSN :
- 11791322
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Cancer Management and Research
- Accession number :
- edsair.doi...........190a1280c24ee5eeb430cce6fcee02bd
- Full Text :
- https://doi.org/10.2147/cmar.s197521